Minocycline hepatotoxicity: clinical characterization and identification of HLA-B∗ 35:02 as a risk factor

Minocycline hepatotoxicity can present with prominent autoimmune features in previously healthy individuals. The aim of this study was to identify genetic determinants of minocycline DILI in a well-phenotyped cohort of patients. Methods: Caucasian patients with minocycline DILI underwent genome-wide...

Full description

Bibliographic Details
Main Authors: Urban, Thomas Jacob, Nicoletti, Paola, Chalasani, Naga, Serrano, Jose, Stolz, Andrew, Daly, Ann K., Aithal, Guruprasad P., Dillon, John F., Navarro, Victor, Odin, Joseph, Barnhart, Huiman X., Ostrov, David, Long, Nanye, Cirulli, Elizabeth Theresa, Watkins, Paul Brent, Fontana, Robert John
Format: Article
Published: Elsevier 2017
Subjects:
Online Access:https://eprints.nottingham.ac.uk/41683/
_version_ 1848796330014539776
author Urban, Thomas Jacob
Nicoletti, Paola
Chalasani, Naga
Serrano, Jose
Stolz, Andrew
Daly, Ann K.
Aithal, Guruprasad P.
Dillon, John F.
Navarro, Victor
Odin, Joseph
Barnhart, Huiman X.
Ostrov, David
Long, Nanye
Cirulli, Elizabeth Theresa
Watkins, Paul Brent
Fontana, Robert John
author_facet Urban, Thomas Jacob
Nicoletti, Paola
Chalasani, Naga
Serrano, Jose
Stolz, Andrew
Daly, Ann K.
Aithal, Guruprasad P.
Dillon, John F.
Navarro, Victor
Odin, Joseph
Barnhart, Huiman X.
Ostrov, David
Long, Nanye
Cirulli, Elizabeth Theresa
Watkins, Paul Brent
Fontana, Robert John
author_sort Urban, Thomas Jacob
building Nottingham Research Data Repository
collection Online Access
description Minocycline hepatotoxicity can present with prominent autoimmune features in previously healthy individuals. The aim of this study was to identify genetic determinants of minocycline DILI in a well-phenotyped cohort of patients. Methods: Caucasian patients with minocycline DILI underwent genome-wide genotyping and were compared to unexposed population controls. Human leukocyte antigen (HLA) binding of minocycline was assessed using AutoDock Vina. Results: Amongst the 25 cases, 80% were female, median age was 19 years and median latency from drug start to DILI onset was 318 days. At presentation, 76% had acute hepatocellular liver injury, median ALT 1077 U/L (range: 63 to 2333), median bilirubin 4.5 mg/dl (range: 0.2 to 16.7), and 90% had a +ANA. During follow-up, 50% were treated with corticosteroids and no subjects died or required a liver transplant. A significant association was noted between HLA-B∗35:02 and risk for minocycline-DILI; a 16% carrier frequency in DILI cases compared to 0.6% in population controls (Odds Ratio: 29.6, 95% CI: 7.8-89.8, p=2.5 x 10-8). Verification of HLA-B∗35:02 imputation was confirmed by sequence-based HLA typing. HLA-B∗35:02 carriers had similar presenting features and outcomes compared to non-carriers. In silico modeling studies support the hypothesis that direct binding of minocycline to this novel HLA risk allele might be an important initiating event in minocycline-DILI. Conclusion: HLA-B∗35:02 is a rare HLA allele that was more frequently identified in the 25 minocycline-DILI cases compared to population controls. If confirmed in other cohorts, this HLA allele may prove to be a useful diagnostic marker of minocycline DILI.
first_indexed 2025-11-14T19:46:16Z
format Article
id nottingham-41683
institution University of Nottingham Malaysia Campus
institution_category Local University
last_indexed 2025-11-14T19:46:16Z
publishDate 2017
publisher Elsevier
recordtype eprints
repository_type Digital Repository
spelling nottingham-416832020-05-04T18:38:19Z https://eprints.nottingham.ac.uk/41683/ Minocycline hepatotoxicity: clinical characterization and identification of HLA-B∗ 35:02 as a risk factor Urban, Thomas Jacob Nicoletti, Paola Chalasani, Naga Serrano, Jose Stolz, Andrew Daly, Ann K. Aithal, Guruprasad P. Dillon, John F. Navarro, Victor Odin, Joseph Barnhart, Huiman X. Ostrov, David Long, Nanye Cirulli, Elizabeth Theresa Watkins, Paul Brent Fontana, Robert John Minocycline hepatotoxicity can present with prominent autoimmune features in previously healthy individuals. The aim of this study was to identify genetic determinants of minocycline DILI in a well-phenotyped cohort of patients. Methods: Caucasian patients with minocycline DILI underwent genome-wide genotyping and were compared to unexposed population controls. Human leukocyte antigen (HLA) binding of minocycline was assessed using AutoDock Vina. Results: Amongst the 25 cases, 80% were female, median age was 19 years and median latency from drug start to DILI onset was 318 days. At presentation, 76% had acute hepatocellular liver injury, median ALT 1077 U/L (range: 63 to 2333), median bilirubin 4.5 mg/dl (range: 0.2 to 16.7), and 90% had a +ANA. During follow-up, 50% were treated with corticosteroids and no subjects died or required a liver transplant. A significant association was noted between HLA-B∗35:02 and risk for minocycline-DILI; a 16% carrier frequency in DILI cases compared to 0.6% in population controls (Odds Ratio: 29.6, 95% CI: 7.8-89.8, p=2.5 x 10-8). Verification of HLA-B∗35:02 imputation was confirmed by sequence-based HLA typing. HLA-B∗35:02 carriers had similar presenting features and outcomes compared to non-carriers. In silico modeling studies support the hypothesis that direct binding of minocycline to this novel HLA risk allele might be an important initiating event in minocycline-DILI. Conclusion: HLA-B∗35:02 is a rare HLA allele that was more frequently identified in the 25 minocycline-DILI cases compared to population controls. If confirmed in other cohorts, this HLA allele may prove to be a useful diagnostic marker of minocycline DILI. Elsevier 2017-03-18 Article PeerReviewed Urban, Thomas Jacob, Nicoletti, Paola, Chalasani, Naga, Serrano, Jose, Stolz, Andrew, Daly, Ann K., Aithal, Guruprasad P., Dillon, John F., Navarro, Victor, Odin, Joseph, Barnhart, Huiman X., Ostrov, David, Long, Nanye, Cirulli, Elizabeth Theresa, Watkins, Paul Brent and Fontana, Robert John (2017) Minocycline hepatotoxicity: clinical characterization and identification of HLA-B∗ 35:02 as a risk factor. Journal of Hepatology . ISSN 1600-0641 Drug induced liver injury Single nucleotide polymorphism Genetic association Autoimmunity Human leukocyte antigen https://doi.org/10.1016/j.jhep.2017.03.010 doi:10.1016/j.jhep.2017.03.010 doi:10.1016/j.jhep.2017.03.010
spellingShingle Drug induced liver injury
Single nucleotide polymorphism
Genetic association
Autoimmunity
Human leukocyte antigen
Urban, Thomas Jacob
Nicoletti, Paola
Chalasani, Naga
Serrano, Jose
Stolz, Andrew
Daly, Ann K.
Aithal, Guruprasad P.
Dillon, John F.
Navarro, Victor
Odin, Joseph
Barnhart, Huiman X.
Ostrov, David
Long, Nanye
Cirulli, Elizabeth Theresa
Watkins, Paul Brent
Fontana, Robert John
Minocycline hepatotoxicity: clinical characterization and identification of HLA-B∗ 35:02 as a risk factor
title Minocycline hepatotoxicity: clinical characterization and identification of HLA-B∗ 35:02 as a risk factor
title_full Minocycline hepatotoxicity: clinical characterization and identification of HLA-B∗ 35:02 as a risk factor
title_fullStr Minocycline hepatotoxicity: clinical characterization and identification of HLA-B∗ 35:02 as a risk factor
title_full_unstemmed Minocycline hepatotoxicity: clinical characterization and identification of HLA-B∗ 35:02 as a risk factor
title_short Minocycline hepatotoxicity: clinical characterization and identification of HLA-B∗ 35:02 as a risk factor
title_sort minocycline hepatotoxicity: clinical characterization and identification of hla-b∗ 35:02 as a risk factor
topic Drug induced liver injury
Single nucleotide polymorphism
Genetic association
Autoimmunity
Human leukocyte antigen
url https://eprints.nottingham.ac.uk/41683/
https://eprints.nottingham.ac.uk/41683/
https://eprints.nottingham.ac.uk/41683/